Could Psychedelics Be the Drugs That Bridge the Peace Gap?

December 3, 2020 10:35:20

For the first time, Israel treated patients who suffered from post-traumatic stress disorder with MDMA-assisted psychotherapy in February of this year. This was part of the Phase 3 trials of MDMA, which are a part of a research initiative being carried out in collaboration with the Multidisciplinary Association for Psychedelic Studies (“MAPS”), which is based in the United States. This initiative encompasses 15 sites in Israel, Canada and the U.S. and is expected to end in the last quarter of next year. The body anticipates that it will receive full regulatory approval from the FDA.

The first trial that was conducted on MDMA attained an 83% rate of success in PTSD-symptom alleviation. Its results, which were reported in 2010, showed that the treatment outcomes were sustained throughout the duration of the study. Recent studies have shown that MDMA produces much better therapeutic results in comparison with FDA-approved drugs for PTSD. This led to the FDA granting breakthrough designation for MDMA in 2017.

Last year, the director of the psychological trauma unit in the Israeli Ministry of Health, Bella Ben Gershon, announced a 68% rate of success for patients involved in a clinical trial whose symptoms of PTSD had been resistant to the conventional treatments. PTSD plays a rather major role in the sustaining and aggravation of conflict.

Therefore, leading a science initiative in the Middle East may be a good way for the U.S. to achieve interdependent diplomatic agreements that address security concerns. Psychedelic drug applications in the treatment of PTSD is a promising area to center on with regard to research. This may also be applied to conflict resolution and reform in the security sector as well as as a way to counter violent extremism over time. Recent decisions between Israel and both UAE and Bahrain to take part in scientific cooperation and engage in regional science diplomacy only supports this argument.

Apart from MDMA, U.S. veterans have been exploring the treatment of PTSD using ayahuasca. Scientific evidence also shows that 5-MeO-DMT and ibogaine may help speed up the post-traumatic stress disorder healing process and any symptoms related to it. These results were published in the “Chronic Stress” scientific journal in July of this year.

Estimates show that nearly 8 million Americans suffer from post-traumatic stress disorder while in Israel approximately 10% of the country’s population suffer from the same. While psychedelics may not be the cure to other problems that plague our world, they may be the cure to various diseases that plague a large part of the population. These drugs may be a breakthrough drug in the medical field, and they may help bridge the gap between various diplomacies, making them even more valuable substances.

The psychedelics and functional mushrooms sectors are seeing a lot of activity of late. For example, Pure Extracts Technologies Corp. (CSE: PULL) is uniquely positioned to be a leading player in the functional mushrooms space in not only Canada but internationally as well.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.